A Phase 1 interventional study of IM-1340 in Colorectal Cancer, Non-Small Cell Lung Cancer and Small Cell Lung Cancer, sponsored by Immunome, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Immunome, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will test the safety and effectiveness of a drug called IM-1340 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
This study will have two parts. Part A will test increasing doses of IM-1340 to find out the safe dose and schedule of IM-1340 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1340 and if it works to treat solid tumor cancers.
This is a Phase 1 open-label, multicenter, dose escalation and expansion study designed to determine the safety, tolerability, PK, and preliminary antitumor activity of IM-1340 administered to participants with advanced solid tumors. The study consists of 2 parts:
Part A: A dose-escalation phase to evaluate the safety and tolerability of IM-1340 to determine the recommended dose for expansion (RDE) and evaluate maximum tolerated dose (MTD) and/or maximum achievable dose.
Part B: An expansion phase to further evaluate the safety and preliminary antitumor activity of IM-1340 monotherapy.
6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
This study's planned enrollment of 200 is above the median of 76 across 4,809 interventional studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →Immunome, Inc. is the lead sponsor of 11 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Histological diagnosis including but not limited to one of the following advanced solid tumors:
Part A
High-grade neuroendocrine neoplasms (NENs)
Part B
Participants must have disease that is considered to be incurable and meet the appropriate criteria below:
Part A:
Part B:
Cohort B1 (ES-SCLC):
Cohort B2 (non-sq NSCLC):
Exclusion Criteria:
Previously treated with an ADC with a DNA topoisomerase inhibitor (TOP1) payload
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IM-1340 given into the vein (IV; intravenously)
Drug: IM-1340
IM-1340 given into the vein (IV; intravenously)
Drug: IM-1340
IM-1340 is an antibody-drug conjugate (ADC)
Evaluate the safety and tolerability of IM-1340 in participants with advanced solid tumors
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0, including serious adverse events, AEs of interest, AEs leading to treatment discontinuation, and deaths.
Time frame: Through 30 days after last dose of study treatment; approximately 12 months
Characterize the PK of IM-1340 in participants with advanced solid tumors by area under the concentration-time curve (AUC)
Pharmacokinetic (PK) parameter
Time frame: Through 30 days after last dose of study treatment; approximately 12 months
Characterize the PK of IM-1340 in participants with advanced solid tumors by maximum observed concentration (Cmax)
PK parameter
Time frame: Through 30 days after last dose of study treatment; approximately 12 months
Characterize the PK of IM-1340 in participants with advanced solid tumors by time to maximum observed concentration (Tmax)
PK parameter
Time frame: Through 30 days after last dose of study treatment; approximately 12 months
Characterize the PK of IM-1340 in participants with advanced solid tumors by trough concentration (Ctrough)
PK parameter
Time frame: Through 30 days after last dose of study treatment; approximately 12 months
Characterize the immunogenicity of IM-1340
Incidence of antidrug antibodies (ADA)
Time frame: Through 30 days after last dose of study treatment; approximately 12 months
Evaluate the preliminary antitumor activity of IM-1340 in participants with advanced solid tumors
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the Investigator
Time frame: From start of study until disease progression by RECIST v1.1 or initiation of subsequent anticancer therapy; up to approximately 12 months
Evaluate the preliminary antitumor activity of IM-1340 in participants with advanced solid tumors
Disease Control Rate (DCR) per RECIST v1.1 as assessed by the Investigator
Time frame: From start of study until disease progression by RECIST v1.1 or initiation of subsequent anticancer therapy; up to approximately 12 months
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Sep 2030, 46 months later.
Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 46 months is close to that.
Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.